(Q38086611)

28 August 2017

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease (English)

1 reference

28 August 2017

1 reference

André J Scheen

1

1 reference

PubMed ID

23461781

28 August 2017

language of work or name

English

0 references

publication date

6 March 2013

1 reference

Expert Opinion on Drug Metabolism & Toxicology

28 August 2017

1 reference

28 August 2017

9

1 reference

28 August 2017

5

1 reference

28 August 2017

529-550

1 reference

28 August 2017

Leptin and renal disease

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Chronic kidney disease in type 2 diabetes patients in France: prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Temporal trends in the prevalence of diabetic kidney disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Selection and dosing of medications for management of diabetes in patients with advanced kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Management of glycemia in patients with diabetes mellitus and CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Limitations and future treatment options in type 2 diabetes with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Management of diabetes in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Medications in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Oral antidiabetic agents. A guide to selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacologic management of the older patient with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Estimation of renal function in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Evaluation of Modification of Diet in Renal Disease Study and Cockcroft-Gault equations for sitagliptin dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Lactic acidosis in biguanide-treated diabetics: a review of 330 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Lactic acidosis induced by metformin: incidence, management and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Contraindications can damage your health--is metformin a case in point?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Clinical pharmacokinetics of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Clinical Pharmacokinetics of Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Disposition of metformin (N,N-dimethylbiguanide) in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Measurement of the renal clearance of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Kidney function and age are both predictors of pharmacokinetics of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Metformin therapy in patients with chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Use of metformin in the setting of mild-to-moderate renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

A risk-benefit assessment of metformin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Metformin use in renal dysfunction: is a serum creatinine threshold appropriate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Limitations of metformin use in patients with kidney disease: are they warranted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Renal status among patients using metformin in a primary care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Metformin use and mortality among patients with diabetes and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Review: metformin: potential benefits and use in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Metformin in patients with chronic kidney disease: strengths and weaknesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Drug-induced hypoglycaemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Frequency of hypoglycemia and its significance in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Comparative effectiveness of incident oral antidiabetic drugs on kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Rates of hypoglycemia in users of sulfonylureas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Intervention to decrease glyburide use in elderly patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Repaglinide: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of nateglinide in renally impaired diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Peroxisome proliferator-activated receptor gamma agonists in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Protection of the kidney by thiazolidinediones: an assessment from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

The safety of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Thiazolidinediones and fracture risk in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Rosiglitazone is associated with mortality in chronic hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

The pharmacokinetics of pioglitazone in patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Plasma concentration of pioglitazone in patients with type 2 diabetes on hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Outcomes and lessons from the PROactive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of rosiglitazone in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

A review of gliptins in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Clinical pharmacokinetics and pharmacodynamics of vildagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Efficacy and safety of Jentadueto® (linagliptin plus metformin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Dapagliflozin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Exenatide-associated ischemic renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Effect of renal impairment on the pharmacokinetics of exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Mild renal impairment and the efficacy and safety of liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

The renal metabolism of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Gliclazide modified release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

10.1517/17425255.2013.777428

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23461781